Suven Life Sciences is currently trading at Rs. 218.75, up by 6.10 points or 2.87% from its previous closing of Rs. 212.65 on the BSE.

The scrip opened at Rs. 213.25 and has touched a high and low of Rs. 220.00 and Rs. 213.25 respectively. So far 113768 shares were traded on the counter.

The BSE group 'B ' stock of face value Rs. 1 has touched a 52 week high of Rs. 229.80 on 08-Sep-2014 and a 52 week low of Rs. 54.15 on 01-Nov-2013.

Last one week high and low of the scrip stood at Rs. 220.00 and Rs. 194.15 respectively. The current market cap of the company is Rs. 2535.18 crore.

The promoters holding in the company stood at 64.76% while Institutions and Non-Institutions held 1.97% and 33.27% respectively.

Suven Life Sciences’ NCE ‘SUVN-3031’ has commenced Phase 1 clinical trial in USA. SUVN-G3031 - a potent, selective, brain penetrant and orally active Histamine H3 antagonist for the treatment of cognitive dysfunction associated with Alzheimer ’s disease / Schizophrenia has completed all the preclinical, safety and early toxicological studies, GLP toxicological studies and was submitted for Investigational New Drug Application (IND) to conduct Phase 1 clinical trial with the indication for Cognition in Alzheimer’s Disease under 505(1) of the Federal Food, Drug and Cosmetic Act (FDCA).

Based on the IND ‘A Single Center, Double-blind, Placebo-controlled, Randomized, Phase 1 Study to Evaluate the safety, Tolerability, and Pharmacokinetics of SUVN-G3031 after Single Ascending Doses and Multiple Ascending Doses in Healthy Male Subjects’ for Cognition in Alzheimer’s Disease is underway in USA.

Suven Life Science is a biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products, which are first in class or best in class CNS therapies through the use of GPCR targets